{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:30:26Z","timestamp":1747164626436,"version":"3.40.5"},"reference-count":53,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,11]],"date-time":"2016-09-11T00:00:00Z","timestamp":1473552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","jfma-online.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.jfma.2016.07.013","type":"journal-article","created":{"date-parts":[[2016,10,18]],"date-time":"2016-10-18T01:03:57Z","timestamp":1476752637000},"page":"953-960","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C"],"prefix":"10.1016","volume":"115","author":[{"given":"Yone-Han","family":"Mah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tai-Chung","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Jen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Jer","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ding-Shinn","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2442-7952","authenticated-orcid":false,"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2016.07.013_bib1","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1053\/gast.2002.1232082","article-title":"National Institutes of Health Consensus Development Conference statement: management of hepatitis C 2002 (June 10\u201312, 2002)","volume":"123","author":"National Institutes of Health","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2016.07.013_bib2","series-title":"NIH Consensus Statement on Management of Hepatitis C: 2002","first-page":"1","volume":"Volume 19","author":"National Institutes of Health","year":"2002"},{"key":"10.1016\/j.jfma.2016.07.013_bib3","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","article-title":"Epidemiology of viral hepatitis and hepatocellular carcinoma","volume":"142","author":"El-Serag","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2016.07.013_bib4","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/j.1478-3231.2005.01139.x","article-title":"Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia","volume":"25","author":"Kao","year":"2005","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2016.07.013_bib5","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","article-title":"An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases","volume":"54","author":"Ghany","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2016.07.013_bib6","first-page":"2051","article-title":"Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa","volume":"9","author":"Liu","year":"2014","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.jfma.2016.07.013_bib7","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2016.07.013_bib8","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jfma.2014.09.001","article-title":"Emerging treatments for chronic hepatitis C","volume":"114","author":"Hayes","year":"2015","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2016.07.013_bib9","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0168-8278(05)80403-9","article-title":"A clinicopathologic study of chronic non-A, non-B (type C) hepatitis in Taiwan: comparison between posttransfusion and sporadic patients","volume":"21","author":"Kao","year":"1994","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2016.07.013_bib10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jfma.2015.06.012","article-title":"Hepatitis C virus infection in Taiwan: past, present, and future","volume":"115","author":"Kao","year":"2016","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2016.07.013_bib11","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jfma.2015.06.005","article-title":"Perspectives on dual hepatitis B and C infection in Taiwan","volume":"115","author":"Liu","year":"2016","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2016.07.013_bib12","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)","volume":"352","author":"Poynard","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2016.07.013_bib13","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1086\/498512","article-title":"Hepatitis C virus infection in African Americans","volume":"42","author":"Pearlman","year":"2006","journal-title":"Clin infect Dis"},{"key":"10.1016\/j.jfma.2016.07.013_bib14","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jhep.2009.07.008","article-title":"Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin","volume":"51","author":"Grasso","year":"2009","journal-title":"J Hepatol"},{"issue":"5 Suppl 1","key":"10.1016\/j.jfma.2016.07.013_bib15","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/hep.1840360706","article-title":"Natural history of chronic hepatitis C","volume":"36","author":"Seeff","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2016.07.013_bib16","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1053\/j.gastro.2008.02.069","article-title":"Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors","volume":"134","author":"Missiha","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2016.07.013_bib17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/jgh.12475","article-title":"Role of IL28B for chronic hepatitis C treatment toward personalized medicine","volume":"29","author":"Matsuura","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2016.07.013_bib18","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jfma.2016.07.013_bib19","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.gastro.2010.04.013","article-title":"Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus","volume":"139","author":"Thompson","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2016.07.013_bib20","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.jfma.2016.07.013_bib21","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","article-title":"IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy","volume":"41","author":"Suppiah","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.jfma.2016.07.013_bib22","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2009.12.056","article-title":"Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study","volume":"138","author":"Rauch","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2016.07.013_bib23","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jfma.2016.07.013_bib24","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1053\/j.gastro.2010.07.005","article-title":"A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice","volume":"139","author":"Tillmann","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2016.07.013_bib25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11901-013-0176-4","article-title":"IL28B genotype on HCV infection in Asia","volume":"12","author":"Liu","year":"2013","journal-title":"Curr Hepat Rep"},{"key":"10.1016\/j.jfma.2016.07.013_bib26","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/egh.12.24","article-title":"Genomic variation-guided management in chronic hepatitis C","volume":"6","author":"Hsu","year":"2012","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2016.07.013_bib27","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/hep.24052","article-title":"Hepatitis C pharmacogenetics: state of the art in 2010","volume":"53","author":"Afdhal","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2016.07.013_bib28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group","volume":"24","author":"Bedossa","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2016.07.013_bib29","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1073\/pnas.1100349108","article-title":"Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy","volume":"108","author":"Hsu","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jfma.2016.07.013_bib30","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3851\/IMP2322","article-title":"Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin","volume":"17","author":"Liu","year":"2012","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jfma.2016.07.013_bib31","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.idc.2012.08.010","article-title":"IL28B polymorphisms as a pretreatment predictor of response to HCV treatment","volume":"26","author":"Berger","year":"2012","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.jfma.2016.07.013_bib32","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/hep.24683","article-title":"Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4","volume":"55","author":"De Nicola","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2016.07.013_bib33","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jhep.2011.09.008","article-title":"IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C","volume":"56","author":"Asselah","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2016.07.013_bib34","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jhep.2011.01.050","article-title":"IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C","volume":"55","author":"Bochud","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2016.07.013_bib35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/hep.23624","article-title":"Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes","volume":"52","author":"Montes-Cano","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2016.07.013_bib36","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s10875-011-9547-1","article-title":"Role of interleukin 28B rs12979860 C\/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype","volume":"31","author":"Falleti","year":"2011","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jfma.2016.07.013_bib37","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1053\/j.gastro.2010.02.009","article-title":"Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin","volume":"138","author":"McCarthy","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2016.07.013_bib38","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.3390\/ijms15057213","article-title":"The association of il28b genotype with the histological features of chronic hepatitis C is HCV genotype dependent","volume":"15","author":"D'Ambrosio","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jfma.2016.07.013_bib39","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2013.04.035","article-title":"Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)\u2014NCT01514890","volume":"59","author":"Hezode","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2016.07.013_bib40","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/hep.23340","article-title":"Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis","volume":"51","author":"Bruno","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2016.07.013_bib41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s00535-012-0669-x","article-title":"Host factors determining the efficacy of hepatitis C treatment","volume":"48","author":"Chuang","year":"2013","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jfma.2016.07.013_bib42","doi-asserted-by":"crossref","first-page":"e690","DOI":"10.1097\/MD.0000000000000690","article-title":"Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan","volume":"94","author":"Yu","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.jfma.2016.07.013_bib43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/cld.442","article-title":"New treatments for HCV: perspective from Asia","volume":"5","author":"Yu","year":"2015","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jfma.2016.07.013_bib44","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1440-1746.2009.05789.x","article-title":"Treatment of chronic hepatitis C in Asia: when East meets West","volume":"24","author":"Yu","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2016.07.013_bib45","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12879-015-0888-x","article-title":"Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study","volume":"15","author":"Hu","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jfma.2016.07.013_bib46","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.antiviral.2011.12.002","article-title":"Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1","volume":"93","author":"Huang","year":"2012","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jfma.2016.07.013_bib47","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1471-230X-14-113","article-title":"Association of MRC-1 and IL-28B with the treatment outcome of hepatitis C: a case control study","volume":"14","author":"Peng","year":"2014","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jfma.2016.07.013_bib48","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/jvh.12097","article-title":"Role of hepatitis C virus substitutions and interleukin-28B polymorphism on response to peginterferon plus ribavirin in a prospective study of response-guided therapy","volume":"20","author":"Liang","year":"2013","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jfma.2016.07.013_bib49","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/jgh.12329","article-title":"Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin","volume":"29","author":"Chen","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2016.07.013_bib50","doi-asserted-by":"crossref","first-page":"e18322","DOI":"10.1371\/journal.pone.0018322","article-title":"IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection","volume":"6","author":"Lin","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jfma.2016.07.013_bib51","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3851\/IMP2026","article-title":"Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy","volume":"17","author":"Liu","year":"2012","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jfma.2016.07.013_bib52","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jhep.2011.03.029","article-title":"Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon\/ribavirin","volume":"56","author":"Huang","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2016.07.013_bib53","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/hep.23976","article-title":"Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients","volume":"53","author":"Yu","year":"2011","journal-title":"Hepatology"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664616301991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664616301991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T15:26:21Z","timestamp":1657466781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664616301991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":53,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S0929664616301991"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2016.07.013","relation":{},"ISSN":["0929-6646"],"issn-type":[{"type":"print","value":"0929-6646"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2016.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016, Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}